The new miracle weight-loss jab that’s taking social media by storm may also be causing baldness and “sulfur belching.”
Mounjaro users have reported a series of unexpected and troublesome side effects similar to those caused by a rival injection called Wegovy. These include diarrhea, vomiting and even hair loss.
Overweight people taking tirzepatide, the powerful ingredient behind Munjaro’s phenomenal effects, lost an average of 34.4 pounds (15.6 kg) after 72 weeks, according to yesterday’s groundbreaking trial data. They all adopted a healthier lifestyle while taking a jab once a week.
The results prompted the manufacturer, Eli Lilly and Co, to apply for approval of jab as a weight loss option in the United States. A similar application is expected in the UK later this year.
However, some Americans are already taking it “off label” for weight loss drugs.
Amazing weight loss changes of up to 100 pounds are scattered among the many reports of shedding, with people complaining of hair loss, rashes and digestive problems after taking it.
Emily, 31, from northeastern Indiana, who was 352 pounds (159.7 kg) before starting weight-loss injections and now has lost a whopping 140 pounds (63.5 kg), was named Munjaro in August last year. I have lost about 50 pounds (22.7kg) since switching to
According to the latest data, digestive problems were the most commonly reported side effects of tirzepatide, the active ingredient in Munjaro. included 1, approximately 1 in 10 reporting vomiting or diarrhea
Amanda Staffor from Kentucky posted on TikTok that she lost 50 pounds (22.7 kg) while taking Munjaro. She even claimed that the vomiting she experienced was “worth it.”
However, in another clip, she reveals that she’s lost a fistful of clumps of hair while taking the drug.
“One of the really bad side effects I have is hair loss when I shower,” she says.
She then held a fist-sized lock of hair to the camera and added:
Staffer asked other people taking the drug for advice on the side effect, saying, “Someone please help me. I don’t want to lose all my hair.”
Another Las Vegas woman, Ari Owen, who said she lost 36 pounds (16.3 kg) using Munjaro, also reported a digestive side effect she dubbed “sulfur belching.”
In a TikTok video, the dental clinic manager said:
Other people using this drug have reported other side effects such as injection site rash, dizziness, and dry mouth.
All medicines, from general pain relievers to specialty drugs, have potential side effects that vary in frequency and severity.
Gastrointestinal problems were the most commonly reported side effects, according to the latest Lilly trial of tirzepatide, a study of over 900 obese/overweight people with type 2 diabetes.
These included approximately 1 in 5 participants who suffered from nausea and diarrhea, and approximately 1 in 10 who reported vomiting or diarrhea.
Lilly said side effects were most commonly reported during the dose titration period.
Hair loss wasn’t included in this breakdown of side effects, but similar reports have emerged with other weight loss jabs designed to help people lose weight, like Ozempic and Wegovy.
In this study, which tested two maximum doses of weekly injections, 4% and 7.5% of participants discontinued due to side effects in the 10mg and 15mg cohorts, respectively.
Despite the side effects, hundreds of Americans consider it worth the risk, and dozens have posted amazing transformation videos.
31-year-old Emily from northeastern Indiana had one of those shocking journeys when she originally weighed 352 pounds (159.7 kg).
In a video detailing her experience, she revealed that she had lost a whopping 140 pounds (63.5 kg) since taking weight loss injections 21 months ago.
Kelsey, who is from California, said she has lost 37 pounds (16.8 kg) in 100 days since starting Munjaro in September 2021.
While taking multiple brands of hormones that mimic weight loss jabs on her journey, including Ozempic, she has lost about 50 pounds (22.7 kg) since switching to Mounjaro last August.
“The incredible joy I feel when I look in the mirror right now is unbelievable,” she said.
“I used to cry to myself in front of the mirror. Now I feel like one of the cool kids.
Another TikTok user named Kelsey from California said she lost 37 pounds (16.8 kg) in 100 days after starting Munjaro in September 2021.
She weighed 250 pounds (113.4 kg) before beginning her weight loss journey and described herself as “struggling.”
According to the latest study results of tirzepatide, participants lost an average of 16%, or about 34 pounds (15.6 kg), over 72 weeks when adopting a healthier lifestyle.
Results from a large-scale tirzepatide trial also suggest it’s slightly more potent than its main rival, Wegobee, made by the Danish company Novo Nordisk, which helps people lose 12-15% of their body weight. Research suggests that it helps you lose weight.Liraglutide and orlistat already available on the NHS
The diagram above shows how the weight loss drug tirzepatide works.It works to curb hunger by mimicking the hormones that indicate the body is full.It also indicates that food passes through the stomach by reducing stomach acid production and muscle contractions.
Studies have shown that the diabetes drug tirzepatide, marketed under the brand name Munjaro, resulted in an average weight loss of over 34 pounds (15 kg) in obese or overweight participants.
Importantly, this was significantly higher than those who adopted only a healthier lifestyle and lost only 3.3% of their body weight over 72 weeks.
Currently, tirzepatide is only approved for type 2 diabetes.
But some Americans are already making incredible changes by having their doctors prescribe ‘off-label’ tirzepatide.
Trial results also suggest it’s slightly more powerful than its main rival, Wegovy, made by Danish company Novo Nordisk.
Both jabs work similarly, using artificial hormones to trick your body into thinking you’re already full by suppressing your appetite.
However, tirzepatide, which is offered to people with type 2 diabetes in the United States under the brand name Mounjaro, It differs from Wegovy because it mimics the effects of two hormones instead of one.
Doctors say the exact cause of hair loss in some patients taking these types of jabs is unknown, but it could be caused after rapid weight loss due to a condition called telogen effluvium. Some say it has sex.
Temporary thinning of hair can be caused by hormonal disruptions caused by rapid weight loss or by depriving hair of resources, they say.
Regarding reports of hair loss in people taking Munjaro, a Lilly spokesperson said:
They added that hair loss in participants had been documented in previous clinical trials of tirzepatide.
Hair loss rates were approximately 1 in 100 for placebo and 1 in 20 for participants taking the drug.
“We don’t know the exact cause, but the effects were generally transient in this study,” the spokesperson added.
As with other weight loss jabs, people taking tirzepatide are given an initial dose of 2.5mg once a week.
This is increased every 4 weeks until the target maximum dose is reached.
Participants in the current study were required to maintain an energy deficit of 500 kcal per day and perform 150 minutes of moderate-intensity exercise per week.
Lilly said it expects a decision by U.S. regulators on the approval of tirzepatide for some weight-loss patients by the second half of 2023, telling MailOnline that submissions to its U.K. counterpart will be made later this year. said.
Munjaro was first approved for the treatment of diabetes last year.
Rival jab Wegovy made headlines earlier this year when it became the first jab of its kind to be given the green light by the UK health watchdog.
But it’s expensive, estimated at over £1,000 (about $1,500) per month.
Similar estimates put tirzepatide at about £900 (about $1,000) per month.
Health officials hope that with more weight-loss jabs online, prices will drop, allowing them to reach more people.
NHS statistics show that 64% of UK adults are overweight and are projected to become even fatter in the future.
Obesity not only stretches Britain’s waistline, it also increases health care costs. Between 2014 and 2015, the NHS spent an estimated £6.1bn on treating weight-related diseases such as diabetes, heart disease and some cancers.
About 42% of people in the United States are obese.